| FNGR 0.398 129.53% | CHAI 0.4 57.11% | LGCL 0.0389 -27.02% | CYAB 0.4467 45.36% | NVDA 217.55 -4.57% | CHGA 2.852 2,082.10% | PCG 16.6 -7.52% | NCPL 0.6916 28.41% | NVD 4.05 8.58% | BITO 10.45 -3.06% | IREN 35.45 -12.53% | INTC 89.47 -2.85% | NU 14.3 -3.90% | IBIT 43.9 -3.07% | XTNT 0.384 16.36% | TSLL 8.98 -3.54% | ONDS 7.9 -9.71% | DUO 0.9602 37.56% | AAL 13.64 -0.58% | SOAR 0.2169 5.80% | SOXL 111.34 -9.52% | BTAI 0.1814 -74.76% | TQQQ 71.85 -1.98% | ETHA 18.37 -2.65% | FTFT 2.2188 281.50% | SPCX 141.5 0.45% | PATH 18.15 -0.98% | BMNR 23.8 -7.14% | NOK 10.21 -3.59% | AMZN 266.43 3.97% | MRVL 216.62 -10.28% | SOXS 49.82 9.86% | WHLR 1.07 -4.46% | SQQQ 38.54 2.03% | PLUG 2.19 -3.52% | SOFI 18.06 -5.84% | AEMD 2.49 14.75% | SPDN 8.49 0.12% | QID 14.24 1.42% | MARA 10.67 -10.11% | KEEL 3.23 -7.98% | GDX 99.65 -3.90% | RIVN 16.07 -4.35% | F 13.87 -0.57% | BTG 5.66 -2.92% | AAPL 319.7 1.63% | PURR 11.61 -9.51% | SMR 9.29 -4.62% | VALE 15.03 -1.83% | SPY 769.35 -0.23%

HealthEquity, Inc. (NASDAQ:HQY) Surpasses Earnings and Revenue Estimates

HealthEquity, Inc. (NASDAQ:HQY) is a prominent player in the medical services industry, specializing in providing technology-enabled services that help consumers make informed healthcare decisions. The company offers a range of solutions, including health savings accounts (HSAs) and other consumer-directed benefits. HealthEquity competes with other firms in the healthcare technology sector, striving to deliver value to its customers and shareholders.

On September 2, 2025, HealthEquity reported earnings per share (EPS) of $1.08, surpassing the estimated $0.92. This represents a significant improvement from the $0.86 EPS reported in the same quarter last year. The earnings surprise for this quarter stands at +17.39%, highlighting the company's ability to exceed market expectations consistently. In the previous quarter, HealthEquity also outperformed with an EPS of $0.97 against an anticipated $0.81, resulting in a +19.75% surprise.

HealthEquity's revenue for the quarter ending in July 2025 reached $325.84 million, marking an 8.6% increase compared to the same period last year. This figure exceeded the Zacks Consensus Estimate of $318.81 million by 2.2%. The company's consistent ability to surpass revenue estimates over the past four quarters underscores its strong market position and operational efficiency.

The company's financial metrics provide further insights into its performance. HealthEquity has a price-to-earnings (P/E) ratio of approximately 63.21, indicating that investors are willing to pay over 63 times the company's earnings for its shares. The price-to-sales ratio stands at about 6.18, suggesting that investors are paying $6.18 for every dollar of the company's sales. These ratios reflect investor confidence in HealthEquity's growth potential.

HealthEquity's balance sheet also shows a healthy financial position. The debt-to-equity ratio is 0.52, indicating a moderate level of debt compared to equity. The current ratio of 4.06 suggests that the company has a strong ability to cover its short-term liabilities with its short-term assets. These metrics, combined with the company's recent earnings performance, provide a comprehensive view of HealthEquity's financial health and future prospects.

Published on: September 3, 2025